NCT07863258Recruiting
STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular Carcinoma
Treatment STRATification in Patients With Advanced HEPatocellular Carcinoma (STRATHEP)
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
STRATHEP develops and validates a multimodal AI model to predict treatment response in advanced hepatocellular carcinoma. By integrating digital pathology and MRI radiomics, the project identifies patients likely to benefit from modern systemic therapies, using the RECIST 1.1 framework as the primary benchmark.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 280 (estimated)
- First submitted
- 1 Oct 2026
- Start date
- 15 Oct 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07863258
What you commit to
- Study type: Observational
- Planned participants: 280
- From 15 Oct 2026 to the primary completion date, 31 Dec 2027
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Participants eligible for inclusion in this Study must meet all of the following criteria:
- Male or female, age \> 18 years
- Hepatocellular carcinoma treated with systemic treatment during the disease course
- Histological confirmation of HCC within one year of the start of systemic treatment OR the availability of an MRI of the liver within 6 months of the start of systemic treatment
- Left-over tissue from previous diagnostic biopsy available
- Ability to sign informed consent for secondary use of archival tissue and data collection for study-specific research for patients who are alive and that have not yet reached a 5-year follow-up period.
- Participants eligible for this Study must not meet any of the following criteria:
- Hepatocellular carcinoma not treated systemically
- Other malignancies of the liver, including cholangiocarcinoma
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpital Universitaire de Bruxelles Coordinator of this site? Confirm its status | Anderlecht | Belgium | Recruiting |
| Imelda Ziekenhuis Coordinator of this site? Confirm its status | Bonheiden | Belgium | Recruiting |
| AZ Sint Lucas, Brugge Coordinator of this site? Confirm its status | Bruges | Belgium | Recruiting |
| Universitair Ziekenhuis Antwerpen Coordinator of this site? Confirm its status | Edegem | Belgium | Recruiting |
| UZ Leuven Coordinator of this site? Confirm its status | Leuven | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.